Logo do repositório
 
Publicação

Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference

2022-10Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSousa-Pinto, Bernardo
dc.contributor.authorSchünemann, Holger J.
dc.contributor.authorSá-Sousa, Ana
dc.contributor.authorVieira, Rafael José
dc.contributor.authorAmaral, Rita
dc.contributor.authorAnto, Josep M.
dc.contributor.authorKlimek, Ludger
dc.contributor.authorCzarlewski, Wienczyslawa
dc.contributor.authorMullol, Joaquim
dc.contributor.authorPfaar, Oliver
dc.contributor.authorBedbrook, Anna
dc.contributor.authorBrussino, Luisa
dc.contributor.authorKvedariene, Violeta
dc.contributor.authorLarenas-Linnemann, Desirée
dc.contributor.authorOkamoto, Yoshitaka
dc.contributor.authorVentura, Maria Teresa
dc.contributor.authorAgache, Ioana
dc.contributor.authorAnsotegui, Ignacio J
dc.contributor.authorBergmann, Karl C.
dc.contributor.authorBosnic-Anticevich, Sinthia
dc.contributor.authorBrozek, Jan
dc.contributor.authorCanonica, G. Walter
dc.contributor.authorCANONICA, GIORGIO WALTER
dc.contributor.authorCardona, Victoria
dc.contributor.authorCarreiro-Martins, Pedro
dc.contributor.authorCarreiro Martins, Pedro
dc.contributor.authorCasale, Thomas
dc.contributor.authorCecchi, Lorenzo
dc.contributor.authorChivato, Tomas
dc.contributor.authorChu, Derek K.
dc.contributor.authorCingi, Cemal
dc.contributor.authorCosta, Elísio M.
dc.contributor.authorCruz, Alvaro A.
dc.contributor.authorDel Giacco, Stefano
dc.contributor.authorDevillier, Philippe
dc.contributor.authorEklund, Patrik
dc.contributor.authorFokkens, Wytske J.
dc.contributor.authorGemicioglu, Bilun
dc.contributor.authorHaahtela, Tari
dc.contributor.authorIvancevich, Juan Carlos
dc.contributor.authorIspayeva, Zhanat
dc.contributor.authorJutel, Marek
dc.contributor.authorKuna, Piotr
dc.contributor.authorKaidashev, Igor
dc.contributor.authorKhaitov, Musa
dc.contributor.authorKraxner, Helga
dc.contributor.authorLaune, Daniel
dc.contributor.authorLipworth, Brian
dc.contributor.authorLouis, Renaud
dc.contributor.authorMakris, Michael
dc.contributor.authorMonti, Riccardo
dc.contributor.authorMorais-Almeida, Mario
dc.contributor.authorMösges, Ralph
dc.contributor.authorNiedoszytko, Marek
dc.contributor.authorPapadopoulos, Nikolaos G.
dc.contributor.authorPatella, Vincenzo
dc.contributor.authorPham-Thi, Nhân
dc.contributor.authorRegateiro, Frederico S.
dc.contributor.authorReitsma, Sietze
dc.contributor.authorRouadi, Philip W.
dc.contributor.authorSamolinski, Boleslaw
dc.contributor.authorSheikh, Aziz
dc.contributor.authorSova, Milan
dc.contributor.authorTodo-Bom, Ana
dc.contributor.authorTaborda-Barata, Luis
dc.contributor.authorToppila-Salmi, Sanna
dc.contributor.authorSastre, Joaquin
dc.contributor.authorTsiligianni, Ioanna
dc.contributor.authorValiulis, Arunas
dc.contributor.authorVandenplas, Olivier
dc.contributor.authorWallace, Dana
dc.contributor.authorWaserman, Susan
dc.contributor.authorYorgancioglu, Arzu
dc.contributor.authorZidarn, Mihaela
dc.contributor.authorZuberbier, Torsten
dc.contributor.authorFonseca, Joao A.
dc.contributor.authorBousquet, Jean
dc.contributor.institutionComprehensive Health Research Centre (CHRC) - pólo NMS
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblWiley-Blackwell
dc.date.accessioned2023-03-30T22:16:07Z
dc.date.available2023-03-30T22:16:07Z
dc.date.issued2022-10
dc.descriptionFunding Information: IA reports personal fees from Roxall, Menarini, UCB, Faes Farma, Sanofi, Bial, Amgen, Abbott, Bayer, Organon. SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, personal fees from Purina, other from MASK‐air. VC reports personal fees from Thermofisher. PCM reports personal fees from Abbvie, AZ, Bial, GSK, Mylan, Medinfar, Novartis, Sanofi. LC reports personal fees from Malesci, Menarini, Astra Zeneca, Novartis. AC reports grants and personal fees from Astrazeneca, GSK, Sanofi, personal fees from Boehringer‐Ingelheim, Chiesi, Glenmark, Novartis, personal fees from Mylan, Abdi‐Ibrahim. PD reports personal fees and non‐financial support from Stallergenes Greer, ALK‐Abello, Astra Zeneca, CHIESI, MYLAN/Meda Pharma, Novartis, GlaxoSmithKline, Sanofi, IQVIA personal fees from MENARINI. JAFonseca reports participation in SME that has mHealth technologies for patients with asthma. JCI reports personal fees from Abbott Ecuador, Bago Bolivia, Faes Farma, Laboratorios Casasco, Sanofi. LK reports grants and personal fees from Allergopharma, LETI Pharma,MEDA/Mylan, Sanofi, personal fees from HAL Allergie, Allergy Therapeut., Cassella med, grants from ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotk, and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. VK reports other from Norameda, BerlinCHemie Menarini. PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, Chiesi, GSK, Novartis, Polpharma. DLL reports personal fees from Allakos, Amstrong, Astrazeneca, Chiesi, DBV Technologies, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer, Carnot, grants from Sanofi, Astrazeneca, Novartis, Circassia, UCB, GSK, Purina institute, Abvvie, Lilly, Pfizer. BL reports grants and personal fees from Meda, personal fees from Glenamrk. RL reports grants and personal fees from GSK, AZ, Chiesi, personal fees from Novartis, Sanofi. MM reports personal fees from Novartis, Gsk, Menarini, Az, Chiesi, Sanofi, Pfizer. RM reports personal fees from Angelini Pharma ALK, Allergopharma, Allergy Therapeutics, Friulchem, Hexal, Servier, Klosterfrau, Bayer, FAES, GSK, MSD, Johnson&Johnson, Meda, Stada, UCB, Nuvo, Menarini, Mundipharma, Pohl‐Boskamp, Laboratoire de la Mer, Sidroga, Lek, PRO‐AdWise, grants and personal fees from Bencard, Stallergenes, Ursapharm, HAL BV, grants from Leti, Optima, BitopAG, Hulka, Inmunotek, Cassella‐med GmbH & Co. KG, ASIT biotech, grants, personal fees and non‐financial support from Lofarma, non‐financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero, personal fees and non‐financial support from Novartis. OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., GlaxoSmithKline, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, Paul‐Martini‐Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG Aerztefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, grants from Pohl‐Boskamp, Inmunotek S.L., Biomay, Circassia. NGPapadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. ATB reports personal fees from AstraZeneca, GSK, Novartis, IQVIA/Abbvie, Mylan, Bial, Leti, grants and personal fees from Teva. STS reports personal fees from ERT, Roche products, Novartis, Sanofi Pharma, AstraZeneca, ALK‐ Abelló grants from Glaxo Smith Kline. IT reports grants from GSK, Boehringer Ingelheim, AZ, personal fees from Novartis, Astra Zeneca, Chiesi, TZ reports Organizational affiliations: Committee member: WHO‐Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF). President: Global Allergy and Asthma European Network (GA2LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). Funding Information: MASK‐air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis and Uriach 1 1 Publisher Copyright: © 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
dc.description.abstractBackground: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., “real-world data”). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015–December 2020) by users self-reporting AR (16–90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71–0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1675448
dc.identifier.doi10.1111/all.15371
dc.identifier.issn0105-4538
dc.identifier.otherPURE: 44852971
dc.identifier.otherPURE UUID: 4fb26bc1-2904-4452-be79-cf706cff2de4
dc.identifier.otherScopus: 85131752144
dc.identifier.otherPubMed: 35567393
dc.identifier.urihttp://hdl.handle.net/10362/151435
dc.identifier.urlhttps://www.scopus.com/pages/publications/85131752144
dc.language.isoeng
dc.peerreviewedyes
dc.subjectallergen immunotherapy
dc.subjectallergic rhinitis
dc.subjectco-medication
dc.subjectmultivariable mixed-effects model
dc.subjectreal-world data
dc.subjectImmunology and Allergy
dc.subjectImmunology
dc.titleComparison of rhinitis treatments using MASK-air® data and considering the minimal important differenceen
dc.typejournal article
degois.publication.firstPage3002
degois.publication.issue10
degois.publication.lastPage3014
degois.publication.titleAllergy: European Journal of Allergy and Clinical Immunology
degois.publication.volume77
dspace.entity.typePublication
person.familyNameCANONICA
person.familyNameCarreiro Martins
person.givenNameGIORGIO WALTER
person.givenNamePedro
person.identifier.orcid0000-0001-8467-2557
person.identifier.orcid0000-0002-4129-133X
person.identifier.ridABF-2037-2020
person.identifier.scopus-author-id55412658800
person.identifier.scopus-author-id36114454200
rcaap.rightsopenAccess
relation.isAuthorOfPublication6ea0be72-ad8b-44a7-b5cf-d7020aa021c5
relation.isAuthorOfPublication758dfb54-ce62-4e3f-b3e2-11e96b5cf1c4
relation.isAuthorOfPublication.latestForDiscovery6ea0be72-ad8b-44a7-b5cf-d7020aa021c5

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Allergy_2022_Sousa_Pinto_Comparison_of_rhinitis_treatments_using_MASK_air_data_and_considering_the_minimal_important.pdf
Tamanho:
1.6 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: CHRC - Artigos em revista internacional com arbitragem científica